Nanomedicine innovations for personalized medicine.
Extracellular vesicles and synthetic lipid nanoparticles are hybridized and functionalized to create a hybrid nanoparticle for specific and safe therapeutic in vivo delivery.
Exosomes and Extracellular vesicles (EV)
naturally occurring delivery vehicles
high biocompatibility
highly cell-specific
genetic material and proteins carriers
low immunogenicity
excellent tollerance
Engineered for precise in vivo delivery, Exo-LNPs transfer therapeutic payloads directly to targeted cells, enabling next-generation biologics and active immunotherapies with enhanced efficacy and safety.
Liponanopartcles (LNP)
widely used as drug delivery vesicles
programable targeting
controlled genetic payload
some drawbacks like low biocompatibility and unfavorable immune response.
What are Exo-LNPs?
Exosome–LNP hybrids enable in vivo delivery of active immunotherapies by transferring the payload directly to the targeted cell.
Exo-LNP™ is a proprietary hybrid nanomedicine platform that combines the biological intelligence of exosomes with the scalability and manufacturability of lipid nanoparticles.
By delivering therapies where they are needed most, Exo-LNP™ unlocks a new paradigm in personalized and scalable precision medicine.
Regenerative Solutions
Current Delivery & Technology Challenges
Targeted delivery: Getting cells, biomaterials, growth factors, or extracellular vesicles to the right tissue in vivo without systemic side effects.
Controlled release: Sustained and localized release of therapeutic molecules remains hard to achieve, especially in dynamic tissues.
Biomaterial biocompatibility: Scaffolds and hydrogels need to avoid fibrosis, degradation issues, or chronic inflammation.
Scalability and reproducibility: Manufacturing stem cell products, exosomes, or engineered vectors under GMP conditions at scale is still expensive and technically complex.
Exo-LNP Impact versus “plain” EVs or LNPs
Compared with EVs: better nucleic-acid loading consistency and manufacturability; easier scale-up; more tunable composition.
Compared with LNPs: improved tissue access and potential cell-type tropism in dense ECM or immune-active sites, with possibly lower innate immune activation.
Exo-LNP Highlights
Deeper tissue penetration & tropism. Borrowing EV surface lipids/proteins or fully “exosome-inspired” shells can improve ECM penetration and homing versus conventional LNPs—important in fibrotic, ischemic, or avascular tissues.
Immune quieting & biocompatibility. EV components can reduce reactogenicity while retaining LNP-like NA loading/scale.
Versatile cargo. mRNA/miRNA/protein delivery relevant to regeneration (e.g., pro-angiogenic, anti-inflammatory, antifibrotic programs).
Future Directions
Neurological Disorders (Crossing the BBB)
Native exosomes cross the blood–brain barrier more efficiently than LNPs. Exo-LNPs could enhance delivery of:
mRNA for neurodegenerative diseases (Parkinson’s, ALS, Alzheimer’s).
Gene-editing payloads in rare CNS diseases.
Anti-inflammatory agents for multiple sclerosis or traumatic brain injury.
Infectious Diseases
mRNA vaccines: exo-LNPs may improve stability and reduce innate immune activation compared to classical LNPs.
Targeting tissues poorly reached by standard LNP vaccines (e.g. mucosal immunity for respiratory viruses, HIV reservoirs).
Delivery of CRISPR antivirals to infected cells.
Metabolic & Cardiovascular Diseases
Targeting adipose tissue, muscle, or myocardium — where classical LNP biodistribution is poor.
mRNA for angiogenesis post-MI.
siRNA for PCSK9 or other lipid regulators.
Modulating inflammation in atherosclerosis.
Frequent Questions
What is nanomedicine?
Nanomedicine involves using nanotechnology for precise therapeutic delivery directly in patients, enhancing treatment efficacy and minimizing invasiveness.
How does Exosiris work?
What are CAR-T cells?
What is targeted protein administration?
Who can benefit from your therapies?
CAR-T cells are a type of immune cell that has been genetically engineered to recognize and kill cancer cells. These are patient-derived T lymphocytes modified to express a synthetic receptor called "chimeric antigen receptor" (CAR) that enables them to recognize and kill specific cancer cells.
Our platform enables biologic cargo delivery directly to patients, facilitating in-body engineering of CAR-T cells and regenerative medicine for effective treatment.
Exosiris exploits Exo-LNPs, hybrid nanocarriers that combine the natural targeting and biocompatibility of exosomes with the scalable delivery efficiency and specificity of lipid nanoparticles.
Targeted protein administration is a method to deliver proteins precisely where they are needed in the body.
What is regenerative medicine?
Biomedical science that aims to repair, replace, or regenerate damaged cells, tissues, and organs to restore normal function using approaches such as stem cells, tissue engineering, and biomaterials.
CAR-T cells technology present major drawbacks
Although a major success in leukemia, current CAR-T therapy has shown frequent relapses and no second infusion is allowed. Besides, it presents a very high cost of manufacturing and efficacy in solid tumor has not been demonstrated.